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ABSTRACT  
   
Major advancements in biology and medicine have been realized during 
recent decades, including massively parallel sequencing, which allows researchers to 
collect millions or billions of short reads from a DNA or RNA sample. This capability 
opens the door to a renaissance in personalized medicine if effectively deployed. 
Three projects that address major and necessary advancements in massively parallel 
sequencing are included in this dissertation. The first study involves a pair of 
algorithms to verify patient identity based on single nucleotide polymorphisms 
(SNPs). In brief, we developed a method that allows de novo construction of sample 
relationships, e.g., which ones are from the same individuals and which are from 
different individuals. We also developed a method to confirm the hypothesis that a 
tumor came from a known individual. The second study derives an algorithm to 
multiplex multiple Polymerase Chain Reaction (PCR) reactions, while minimizing 
interference between reactions that compromise results. PCR is a powerful technique 
that amplifies pre-determined regions of DNA and is often used to selectively amplify 
DNA and RNA targets that are destined for sequencing. It is highly desirable to 
multiplex reactions to save on reagent and assay setup costs as well as equalize the 
effect of minor handling issues across gene targets. Our solution involves a binary 
integer program that minimizes events that are likely to cause interference between 
PCR reactions. The third study involves design and analysis methods required to 
analyze gene expression and copy number results against a reference range in a 
clinical setting for guiding patient treatments. Our goal is to determine which events 
are present in a given tumor specimen. These events may be mutation, DNA copy 
number or RNA expression. All three techniques are being used in major research 
and diagnostic projects for their intended purpose at the time of writing this 
manuscript. The SNP matching solution has been selected by The Cancer Genome 
  ii 
Atlas to determine sample identity. Paradigm Diagnostics, Viomics and International 
Genomics Consortium utilize the PCR multiplexing technique to multiplex various 
types of PCR reactions on multi-million dollar projects. The reference range-based 
normalization method is used by Paradigm Diagnostics to analyze results from every 
patient. 
  
  iii 
ACKNOWLEDGEMENTS 
 
I would like to thank all of those who helped develop and refine this 
dissertation. First, I would like to thank the members of the committee: Esma Gel, 
George Runger, Joseph Paulauskis and Ronald Askin for their assistance in 
developing the mathematical representations of these problems, and refining the 
ideas. I would like to thank Robert Penny for providing initial vision for the Paradigm 
test, as well as access to laboratory space, funding and patient specimens required 
to develop and verify these methods.
  iv 
TABLE OF CONTENTS  
CHAPTER                                                                                                      Page 
1     INTRODUCTION ................. ...................................................................  1  
     2     TWO ALGORITHMS FOR BIOSPECIMEN COMPARISON AND DIFFERENTIATION 
USING SNP GENOTYPES ………………………………………………………...............4  
Abstract ................................................................................... 4  
Introduction ............................................................................. 4  
Methods ................................................................................... 6  
Results  ................................................................................. 19  
Discussion .............................................................................. 26  
3     OPTIMAL HIGH DENSITY MULTIPLEXING OF QUANTITATIVE PCR ................  30  
Abstract ................................................................................. 30  
Introduction ........................................................................... 30  
Methods ................................................................................. 34  
Simulation  ............................................................................ 38  
Case Study  ............................................................................ 42  
Discussion .............................................................................. 44  
     4      ROBUST NORMALIZATION OF MULTIPLEXED QUANTITATIVE MOLECULE  
                     COUNTING ASSAYS AGAINST A KNOWN REFERENCE RANGE .......  47  
Abstract ................................................................................. 47  
Introduction ........................................................................... 47  
Methods ................................................................................. 56  
Simulation  ............................................................................ 63  
Application  ............................................................................ 73  
Discussion .............................................................................. 76 
5     CONCLUSIONS AND FUTURE WORK ........................................................  78 
   REFERENCES................................................................................................ 81 
 1 
CHAPTER 1 
INTRODUCTION 
Nucleic acid polymers, including deoxyribonucleic acid (DNA) and ribonucleic 
acid (RNA), play a critical role in life. DNA contains the genetic information and 
instructions required to run cells. RNA plays a key role in coding, regulation and 
expression of genes. In the most basic model of molecular biology, RNA is 
transcribed from DNA and is initially identical to gene regions in the DNA. RNA 
processing then occurs, which removes certain regions called introns to create the 
final messenger RNA (mRNA). The mRNA is then translated into proteins, which in 
turn conduct cellular processes (Krebs 2009). For example, proteins may be 
structural units of cells, enzymes that conduct chemical reactions, transporters that 
move other molecules throughout the cell, or may participate in signal transduction 
pathways that regulate other cellular processes. While many exceptions to this model 
have been identified, it is sufficient to explain the bulk of processes within the cell 
(Krebs 2009). 
Both DNA and RNA are linear polymers that consist of nucleosides and a 
backbone. There are four different nucleosides that may make up the polymer, and 
the order of these nucleosides when read from one end to the other determines 
which protein is created. The sequence of the RNA, which is in turn determined to a 
large extent by the sequence of the DNA region that encodes it, determines the 
initial sequence of a nascent peptide. Many changes occur while processing a nascent 
peptide into a protein, but alterations in the DNA are usually found in the final 
protein in a manner that is highly predictable (Krebs 2009). This, combined with the 
high level of stability and ease of sequencing DNA, leads to DNA sequencing being 
the primary method used in clinical practice to determine alterations in the code of 
protein (Slebos 1990). mRNA serves as the messenger between the DNA and 
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protein, making the level of mRNA present (often referred to as expression) an 
indicator of how much protein is present (Gry 2009), although this not always true 
(Gygi 1999). One could ask why the surrogates of DNA and RNA are used rather 
than analyzing protein directly. While this would be ideal, protein is very 
heterogeneous, and thus, it is hard to measure accumulation (Chandra 2011) or 
sequence (Wang 2011) of many proteins simultaneously, while the homogenous 
nature of DNA (Davey 2011) and RNA (Martin 2011) makes it easy to analyze 
millions or billions of molecules simultaneously. 
Many human medical conditions, including cancer, are caused by altered 
expression or coding of proteins. Current theory states that cancer is driven by a 
breakdown of signal transduction pathways that are responsible for important 
cellular “decisions” (Krebs 2009). For example, the decision of when to proliferate 
into more cells may be changed to allow growth of healthy cells into a tumor 
(DeBerardinis 2008), and the decision to initiate apoptosis (Ouyang 2012), or 
programmed death of the cell, may be prevented. For example, the KRAS gene is an 
“on/off” switch that controls the cellular decision to proliferate (Bryant 2014). While 
other signals usually control KRAS, certain mutations in this gene create a version of 
the protein that is always switched “on”, leading to cellular proliferation (Lievre 
2006), which is a hallmark of cancer. Another gene, ERBB2, is a sensor for signals 
that lead to proliferation (Liu 2011). If this gene is overexpressed, i.e., there is 
excessive ERBB2 present, the cell becomes highly sensitive to growth signals, 
leading the cell to respond to normal levels of growth factors as if there were a signal 
to begin proliferation (Menard 2004). As before, this leads to proliferation of the cell. 
Within recent years, methods with the ability to detect DNA and RNA with a 
high level of accuracy have been developed. One technology called nCounter 
(Nanostring Technologies, Seattle, WA) can detect molecules directly from purified 
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isolates (Malkov 2009). PCR allows the quantity of a pre-specified sequence of DNA 
or RNA to be doubled in a sequential process (Mullis 1987). Once the number of 
molecules present reaches a detectable level, the original amount can be estimated 
by considering the number of times the quantity was doubled (Taylor 2010). For 
example, if 10,240 molecules are present after being doubled 10 times, it is clear 
that the original number present was !"#$"!!" = 10. Next-gen sequencing includes a wide 
variety of technologies that can sequence individual strands of DNA (Hou 2010). 
While these were originally used to ascertain the sequence of DNA strands and 
determine whether mutations existed (Schuster 2007), it quickly became evident 
that the relative amounts of various molecules, such as DNA or RNA, could also be 
determined (Ekblom 2011). In brief, many molecules are sequenced, the identity of 
each one is determined by comparing its sequence to a list of known sequences, 
then relative differences between abundances of different molecules are examined. 
From these results, one can determine which genes have altered expression (Martin 
2011).  
For example, if one gene shows much higher relative expression than the 
others and is known to drive cancer when overexpressed, one can speculate that the 
gene is driving the cancer and targeting it with a drug may reduce tumor size or 
growth (Von Hoff 2010). This is a form of the affirming the consequent logical 
fallacy, and thus the use of these results is not perfect. Despite this fallacy, when a 
potent oncogene is active, it frequently is driving the cancer. 
Molecular biology and next-gen sequencing provide powerful tools to 
understand cancer. Well-designed mathematical tools can process data, determine 
the underlying drivers of cancer, and determine which drug a patient should receive 
to treat their cancer. 
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CHAPTER 2 
TWO ALGORITHMS FOR BIOSPECIMEN COMPARISON AND DIFFERENTIATION USING 
SNP GENOTYPES 
 
Abstract 
Aims: Biobanks are frequently required to verify specimen relationships.  We 
present two algorithms to compare single nucleotide polymorphism genotype 
patterns that provide an objective, high-throughput tool for verification.  Methods: 
The first algorithm allows for comparison of all holdings within a biobank, and is well 
suited to construct sample relationships de novo for comparison to assumed 
relationships.  The second algorithm is tailored to oncology, and allows one to 
confirm that paired DNAs from malignant and normal tissues are from the same 
individual in the presence of copy number variations.  To evaluate both algorithms, 
we used an internal training data set (n=1504) and an external validation data set 
(n=1457).  Results: In comparison to the results from manual review and a priori 
knowledge of patient relationships, we identified no errors in interpreting sample 
relationships within our validation data set.  Conclusion:  We provide an efficient and 
objective method of automated data analysis that is lacking for establishing and 
verifying specimen relationships in biobanks. 
 
Introduction 
Biobanks play a critical role in large-scale genomics projects such as The 
Cancer Genome Atlas (TCGA) and the International Cancer Genome Consortium 
(ICGC).  A primary responsibility of biobanks is to ensure proper chain of custody for 
specimens, and maintain detailed information about specimen relationships (Hirtzlin 
2003).  For example, a biobank must know which specimens came from a particular 
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patient, and must ensure that specimens derived from a single patient are not 
tracked as originating from different patients.  
As the era of “big science” in genomics matures and collaborative efforts 
involving hundreds of institutions with varying protocols become common (The 
International Cancer Genome Consortium 2010), many biobanks are no longer able 
to maintain full chain of custody for their samples and thus are often unaware of 
errors in specimen relationships. During our experience in the TCGA project 
(McLendon 2008) (Cancer Genome Atlas Research Network 2011), we found 
approximately two percent of samples are not derived from the individual identified.  
For example, a tumor specimen may be incorrectly diagnosed upon pathological 
review or a diseased/non-diseased pair may not originate from the same individual 
upon genotyping.  Common genomic analysis techniques such as DNA/RNA 
sequencing are part of many projects and can be used to detect errors in specimen 
relationships with a high level of accuracy.  However, DNA/RNA sequencing is 
expensive and analyzing results can be time consuming.  It is highly desirable to 
detect inconsistencies in specimen relationships prior to conducting expensive 
analysis such as sequencing (Glenn 2011).  
Two genotyping methods are commonly available to establish and verify 
specimen relationships: short tandem repeats (STR) and single nucleotide 
polymorphisms (SNPs).  STR has high discriminatory power for each locus 
(Rosenberg 2002) (Moretti 2001) (Lin 1995), and is available commercially for 
forensic analysis (AmpFISTR; Applied Biosystems, Carlsbad, CA). However, STRs are 
susceptible to microsatellite instability in many cancers, making them less suitable 
for doing comparisons that involve malignant specimens (Vauhkonen 2004).  SNPs 
tend to have a lower discriminatory power per locus (Sanchez 2006), but are less 
likely to experience changes in cancer. Both SNPs and STRs can be impacted by copy 
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number events in DNA, especially loss of heterozygosity (LOH) in which one allele is 
lost (Bignell 2010).  Because LOH occurs frequently in cancers, standard comparison 
methods may flag properly-paired specimens (i.e., specimens from the same 
individual) as not matching.  
At the time of writing, there is no simple, inexpensive, and rapid method 
available to conduct biobank-wide comparisons to construct specimen relationships 
de novo or to compare diseased/non-diseased specimen pairs from the same 
individual in the presence of significant LOH.  Laboratories specializing in 
malignancies often find that genotypes with LOH can only be effectively compared 
via manual review. This is not scalable as a bank containing just 1,000 specimens 
requires almost 500,000 pair wise comparisons to identify errors in specimen 
relationships such as those due to unexpected duplication of samples from a patient.  
We have developed and evaluated the performance of two algorithms to 
determine specimen relationships.  The first method provides a global comparison of 
specimen SNP results in order to establish de novo relationships between samples.  
The second method provides a tool that is less sensitive to copy number 
abnormalities but is well-suited to confirm that a given pair of malignant and 
disease-free tissues is indeed from the same patient.  The aim of this study is to 
offer an efficient method to perform specimen relationship verification based on SNP 
results in fairly large datasets (with up to 100,000 specimens) on a common laptop 
or desktop computer. 
 
Methods 
  Specimens were procured by the National Cancer Institute for use in the 
TCGA project from multiple biobanks worldwide, and were shipped to either the 
International Genomics Consortium (IGC; Phoenix, AZ) or Nationwide Children's 
 7 
Hospital (NCH; Columbus, OH).  DNA was extracted from whole blood and frozen 
tissue.  Unamplified DNA (10 ng) was used in the genotyping process.  SNP profiles 
were collected using the iPLEX Sample Identification panel (Seq ID) (Sequenom; San 
Diego, CA), a subset of the SNPforID panel (Jin 1995), per manufacturer's 
instructions. 45 multiplexed polymorphic loci were interrogated using Sequenom’s 
Spectrotyper software, which flags results as conservative, moderate, or aggressive, 
based on the level of confidence in the genotype determination per locus.  Data 
collected at IGC was immediately available for algorithm development (referred to as 
the training set; n=1504); whereas, data collected at NCH (referred to as the 
validation set; n=1457) was quarantined until the algorithms had been finalized. 
For both algorithms, we made the assumptions that all SNPs are biallelic; 
each allele occurs with a probability of 0.5, alleles are in Hardy-Weinberg 
equilibrium, and all SNPs are independent of each other. 
 
Algorithm 1: Global Comparison of Specimens 
The global comparison algorithm allows biobank-wide comparisons (i.e., pair 
wise comparisons of all specimens in the bank).  We conducted all possible pair wise 
comparisons of non-diseased specimens, yielding a total of 𝑛2 = 𝑛(𝑛 − 1)/2 
comparisons, where 𝑛 is the number of non-diseased specimens in the bank. 
For each comparison, the algorithm generates a total score that measures the 
amount of similarity between two specimens.  In particular, we obtain this score by 
assigning predetermined values to different types of matches between the SNPs of 
the two specimens on a per-SNP basis.  In the following, the symbol 𝜏 denotes the 
number of SNPs assayed in the panel (i.e., 45 for the Seq ID panel). For each SNP, 
we assign a “SNP Match Score” based on the similarity of the specimens with respect 
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to this SNP, and calculate an aggregate score of similarity by summing the match 
scores for each of the 𝜏 SNPs.  
In our experimental case using the Seq ID panel that assays 45 SNPs, we 
used the scoring rules defined below.  We note that the overall accuracy of the 
algorithm can be tuned for other purposes by adjusting the values of each 
parameter, and we select values for comparison of non-diseased specimens that are 
not expected to experience copy number variants. 
 
Heterozygous SNP Match Score is assigned for comparisons where two specimens 
have matching heterozygous genotypes (e.g., AT and AT) for a particular SNP.  This 
is given a value of +1 in the present study. 
 
Homozygous SNP Match Score is assigned for comparisons where two 
specimens have matching homozygous genotypes (e.g., AA and AA) for a particular 
SNP.  This is given a value of +2 in the present study.  This value is based on the 
fact that a homozygous SNP match will occur by random chance with one half of the 
probability of a heterozygous SNP match, and thus, provides twice as much 
confidence as a heterozygous SNP match. 
 
Missing SNP Score is assigned for comparisons where the genotype is missing 
from at least one of the specimens (i.e., no genotype call was made for the SNP).  
This score is given a value of 0 in this study, because it essentially provides no 
information for comparison. 
 
Heterozygous SNP Mismatch Score is assigned for comparisons where one 
specimen is homozygous, and the other specimen is heterozygous (e.g., AA and AT) 
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for a particular SNP.  This score is given a value of -2 in this study.  This value was 
determined experimentally, using the training set as described in the results section.  
We note that it is possible, albeit rare, that two alleles are present, yet only one is 
detected. 
 
Homozygous SNP Mismatch Score is assigned for comparisons where both 
specimens have homozygous genotypes, but they are different (e.g., AA and TT).  
This is assigned a value of -20.  It is unlikely that a new allele would appear while 
the original allele is lost completely.  The score of -20 allows a specimen match to 
occur with such an event only when the other SNPs show high likelihood of a 
specimen match. 
 
Box 1 provides a pseudocode for the algorithm that calculates the score for 
each pair wise comparison.  The algorithm, after calculating the score, terminates 
with the “match” decision, if the obtained score is higher than the threshold set by 
the user.  Otherwise, the specimens are deemed to “not match”.   
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Box 1: The program code for the scoring strategy of the global comparison 
algorithm. 
 
 To better understand the distribution of the total scores we conduct a few 
theoretical calculations.  If we consider a perfectly matching pair wise comparison of 
specimens (i.e., genotypes for all SNPs are identical between the two specimens) 
and assume that all alleles amplify so that no data is missing, we can obtain the 
distribution of the total score, S, using the binomial distribution since we can model 
the total score as the number of “successes” (i.e., matches) in 𝜏 trials (i.e., each SNP 
is one trial). Hence, the random variable that represents the total score, S, is a 
random variable that changes between 𝜏 and 2𝜏 (i.e., 45 and 90 for the Seq ID 
panel). 
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Recall that a heterozygous SNP match is a “failure” with value +1 
(heterozygous SNP match score) and a homozygous SNP match is a “success” with 
value +2 (homozygous SNP match score). Hence, the random variable 𝑆! = 𝑆 −   𝜏 is 
binominally distributed with parameters 𝜏 and 0.5.  
 The maximum total score attainable is 2𝜏= 90 for our panel, and the expected 
value is  !! 𝜏 = 67.5.  Assuming there are no missing alleles (i.e. did not amplify), it is 
impossible to obtain a total score lower than 45 when two specimens are identical.  
However, if we allow up to five SNPs to be missing due to poor amplification, the 
critical threshold can be set at 40 when determining if two samples are derived from 
the same patient (i.e., matching specimens).  The expected value of the total score 
from a pair of specimens derived from different patients (i.e., non-matching 
specimens) can be calculated to be -135 by conditioning arguments. 
Threshold values were set to define multiple confidence levels for a specimen 
match.  The scores for SNP comparison were summed to a single total score that 
represents the similarity between the two specimens.  A total score of 40-49 was 
considered to be “marginal”, 50-59 was considered to be “low”, 60-69 was 
considered to be “medium”, and greater than 70 was considered to be “high” 
likelihood of similarity.  Alternatively, one could simply have a single threshold of 
matching set at 50. A total score value below 39 was considered to be a non-match 
situation, and hence, was not reported in the output. 
Next, we use some basic graph theory principles to look for unexpected 
matching structures in results.  This analysis was conducted both qualitatively by 
making data easily visualized and quantitatively.  In order to visualize the results of 
all comparisons with matching scores (i.e., total score of at least 40) were exported 
to a text file that was loaded onto a network visualization tool (Shannon 2003).  
Figure 1 shows a scaled-down example of such an output, for a dataset with six 
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specimens, A through F.  We use edge colors to show the confidence of each match 
on a green-yellow-red scale corresponding to the thresholds defined above; with red 
depicting comparisons that meet the highest threshold.  In Figure 1, on right, the 
pair wise comparisons of specimens A, B and C were all matches, resulting in a 
clique in the network visualization.  Cliques are important to observe, since they 
provide an easy method to check for consistency of results, i.e., if A matches B and 
B matches C, we would expect that A also matches C.  In this case, one can reliably 
state that these three specimens are indeed from the same person.  The second 
group on the left of the figure is not a clique; D matches E and E matches F, but D 
does not match F. This would indicate a situation that should be checked manually.  
Multiple methods are available in graph theory to verify that these sub networks are 
cliques quantitatively.  Any network that is not a clique is flagged for more detailed 
manual review.  
 
Figure 1: The results for tissue matching comparisons can be visualized in network 
diagrams. Related samples appear in clique networks with edge colors showing the 
confidence of each identification match on a green-yellow-red scale; red being the 
highest. 
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In order to provide an estimate of false positive rate, we simulated SNP 
results randomly. Because these results were generated randomly, there should be 
no matches found and any match found indicates a false positive. These simulations 
were conducted with different assumptions for minor allele frequency (MAF), starting 
at 50% and decreasing in increments of 5%. In these simulations, we assumed that 
all SNPs had the same MAF. Additionally, we calculated the observed MAF for each 
SNP individually, and randomly generated results using the non-constant observed 
MAF for each SNP. For each simulation, 50,000 patients were simulated, which 
resulted in approximately 1.25 billion pairwise comparisons.  
 
Algorithm 2: Comparison of diseased and non-diseased sample pairs  
When SNP results are obtained from oncology specimens, there is a higher 
chance that there will be LOH and such genetic abnormalities can complicate tissue 
matching.  We have developed a method that is insensitive to LOH and provides a 
systematic, repeatable approach to confirm that a diseased/non-diseased pair is 
indeed from the same patient.  Unlike the previous method, this algorithm is not 
designed to conduct a global (i.e., everything to everything) comparison, but rather 
to confirm the hypothesis that a given pair of specimens is derived from the same 
patient.   
This algorithm eliminates sensitivity to LOH in specimen matching by using 
the non-diseased specimen as the basis of comparison.  Consider a homozygous SNP 
in the non-diseased sample; it should also appear as homozygous in the diseased 
sample, even if LOH has occurred.  However, a heterozygous SNP in the non-
diseased tissue can appear as homozygous in the diseased tissue due to LOH (i.e., if 
one allele is lost), and such an event can mislead inferences on specimen 
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relationships.  Therefore, the algorithm evaluates information only from homozygous 
SNPs in non-diseased specimens and ignores the heterozygous SNPs that may have 
been altered by LOH in the diseased specimen.  A key benefit to this approach is that 
no assumptions are made as to the rate of LOH. 
Since analysis of diseased specimens can be tricky due to genetic abnormality, 
the systematic approach provided by this algorithm is important.  Because this 
method is fairly sensitive to incorrect reads, we exclude SNPs with calls flagged as 
“aggressive” by the Sequenom software.   The algorithm, for a given pair of diseased 
and non-diseased specimens, can be summarized as follows. 
 
1. Ignore SNPs that did not amplify (or had aggressive calls) in either the 
diseased or non-diseased specimen, and retain only those SNPs that are 
present for both.  
2. Obtain SNP results for the non-diseased specimen.  Ignore all SNPs that are 
heterozygous and retain only those that are homozygous. 
3. Obtain SNP results for the diseased specimen and retain results from only 
those SNPs that were homozygous in the non-diseased sample. 
4. Assign 𝑁! to be the number of SNPs retained after steps 1, 2, and 3. 
5. Compare the results from the retained SNPs for the diseased and non-
diseased samples, and assign the number of matching SNPs to 𝑍 
6. If 𝑁! = 𝑍 and 𝑁! ≥ 𝜅, where 𝜅 is a threshold, then the specimens match (i.e. 
derived from the same patient); otherwise, they do not match.  In cases 
where 𝑁! − 𝑍 is low, the results can be flagged for manual review. 
 
Table 1 shows each of the steps on a simple example with seven SNPs.  The first 
three rows depict the number of SNPs retained after the first three steps, which 
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result in 𝑁! = 3  SNPs.  We then observe that S=2 of these remaining SNPs match.  
Because one of the remaining three SNPs doesn't match between the diseased and 
non-diseased specimen (i.e. 𝑁! ≠ 𝑆), we conclude that this sample pair does not 
match. 
 
Table 1: A simplistic representation of the scoring strategy for the tissue matching 
comparison. 
 
The basic process outlined is extremely simple and easy to make calls either 
manually or programmatically.  Thousands of diseased/non-diseased specimen 
pairings can be easily done in a spreadsheet application, or the algorithm can be 
coded using common programming languages. However, before this comparison can 
be done, the correct value of 𝜅, the threshold, must be identified. There are many 
ways to determine the appropriate value of 𝜅. For example, 𝜅 may be chosen such 
that the false positive rate or false negative rate matches a predefined threshold.  
We decided to determine  𝜅 to minimize the overall project costs related to 
false results.  In this context, we will define a failing result as a determination that a 
diseased and non-diseased specimen pair do not match, and a passing result as a 
determination that the specimens match (i.e., the specimen pair is from the same 
patient).  The derivation below shows a method for determining the optimal value for 𝜅 to minimize cost.  We note that the same equations can be used to determine a 
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value of 𝜅 that meets some criteria on the false failing or false passing rate.  This 
derivation is conducted once and the same value of 𝜅 can be maintained as long as 
assumptions are unchanged.  
For the cost formulation, we use the following notation to represent the two 
types of costs. CFP is the cost of a false passing result (in dollars).  This should 
include the cost of conducting downstream analysis before discovering the error or 
the cost of including incorrect data in the downstream analysis.  CFF is the cost of a 
false failing result.  In the case of a false failing result, the specimen will be excluded 
from further analysis and all costs incurred up to this point will be lost.  This should 
include the cost of tissue collection and all lab work conducted prior to and including 
the SNP analysis but no downstream analyses.  
If a total of 𝜏 SNPs are being tested, then the number of SNPs that amplify in 
both diseased and non-diseased specimens (denoted by 𝑁!) will be a random variable 
that is binomially distributed with parameters 𝜏 and 𝑝!, where 𝑝! denotes the 
probability that each SNP will amplify in both diseased and non-diseased specimens.  
This value can be determined by examining historical data and calculating the 
fraction of SNPs for which a result was obtained.  We assume that 𝑝! is the same for 
all SNPs and that the SNPs amplify independently of each other.  That is,  
𝑃 𝑁! = 𝑛 = 𝜏𝑛 𝑝!! 1 − 𝑝!! !!!,          0 ≤ 𝑛 ≤ 𝜏 
Equation 1 
Then, we can calculate the distribution for 𝑀!, the number of homozygotes 
among the 𝑁! SNPs that amplify in both diseased and non-diseased specimens. Given 
the assumption that there are two alleles for each SNP, each with 50% probability of 
occurring, the probability of homozygous genotypes for each SNP of the diseased 
and non-diseased specimen pair is equal to 0.5.  Then, the conditional distribution of 
the random variable 𝑀! given that 𝑁! = 𝑛, is binomial. That is, 
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𝑃 𝑀! = 𝑚 𝑁! = 𝑛 =    𝑛𝑚 0.5 ! 1 − 0.5 !!! = 𝑛𝑚 0.5 !,        for   0 ≤ 𝑚 ≤ 𝑛 
Equation 2 
This allows us to calculate the distribution of 𝑀! for m=0,1,…,  𝜏 as: 
𝑃 𝑀! = 𝑚 = 𝑃 𝑀! = 𝑚 𝑁! = 𝑛 𝑃 𝑁! = 𝑛!!!!  
= 𝑛𝑚 0.5 ! 𝜏𝑛 𝑝!!(1 − 𝑝!!)!!!!!!!  
Equation 3 
In this context, we define a false failing result (denoted by FF below) to be the event 
where less than 𝜅 SNPs amplify and are homozygous. This is the only scenario where 
two correctly paired diseased and non-diseased specimens would obtain a false 
failing result.  Note that our false failing definition contains both those pairings that 
are correct and those that are not.  Thus, it is an upper bound as to the rate of 
pairings that are correctly paired but were unverifiable.  Note that we assume that 
the risk of a passenger mutation causing a new allele in the tumor is trivial.  The 
false failure probability can be expressed as the probability of obtaining an 𝑀!  strictly 
less than 𝜅.  That is, 
𝑃! 𝐹𝐹 = 𝑃 𝑀! < 𝜅 = 𝑃(𝑀! = 𝑚)!!!!!!  
Equation 4 
A false passing result (FP) occurs when 𝑀! ≥ 𝜅 homozygous alleles are present 
and they all match by random chance.  We define 𝑅 to represent the event that any 
diseased specimen SNP will match the non-diseased specimen SNP by random 
chance, given that the non-diseased SNP is a homozygote.  The value of 𝑃(𝑅) is 
calculated as shown below.  The generic notation of a SNP with alleles A and a is 
used.  H is the condition that alleles are homozygous for a given SNP in the non-
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diseased specimen.   𝐿! is defined as the normal allele, and 𝐿! is defined as the tumor 
allele. Then, the probability of the event R can be calculated as  
 𝑃 𝑅 = 𝑃 𝐿! = 𝐴 𝐻 𝑃 𝐿! = 𝐴 + 𝑃 𝐿! = 𝑎 𝐻 𝑃 𝐿! = 𝑎  
Equation 5 
Hence,  𝑃 𝑅 = 0.5 0.25 + 0.5 0.25 = 0.25 
Equation 6	  
The false passing probability can be found by calculating the probability that 
there will be zero mismatches among the 𝑀! =   𝑚 SNPs given that the samples are 
from different individuals.  Conditioning on the distribution of 𝑀! and taking a sum 
over all values of 𝑀!  greater than or equal to 𝜅 we obtain 
𝑃! 𝐹𝑃 = 𝑃 𝑅 !𝑃(𝑀! = 𝑚)!!!!  
Equation 7 
where: 𝑃 zero  mismatches 𝑀! = 𝑚  and  different  individuals = (𝑃 𝑅 )! 
Equation 8 
Now the expected cost, C can be calculated for each value of 𝜅 using: 𝐶! = 𝐶!"𝑃! 𝐹𝑃 + 𝐶!!𝑃! 𝐹𝐹 ,        0 ≤ 𝜅 ≤ 𝜏 
Equation 9 
Because 𝜏 is small and integer (e.g., 𝜏 = 45 for the Seq ID panel), we can 
enumerate the cost for each value of 𝜅 and select the lowest cost.  In our case, we 
found the minimum value of 𝐶! by enumerating all 46 possible values 𝜅 = 0, 1,… , 45. If 
the values for 𝐶!! and 𝐶!" are not readily available, researchers can choose a given 
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𝑃!" or 𝑃!! or can construct ROC curves to determine the appropriate value of  𝜅.  For 
our assumptions, we found that 𝜅 = 10 was optimal. 
 
Results 
The training set included results from 1504 specimens with results for at least 
40 SNPs obtained at IGC during routine processing of specimens for TCGA.  These 
1504 specimens included 285 patients for which at least one pair of diseased and 
non-diseased specimens were available (and thus expected to match).  Prior to 
evaluation of the algorithm, specimen IDs were manually examined to determine the 
specimen relationships so that these can be compared to the ones indicated by the 
two algorithms developed.  Our goal was to determine the effectiveness of the two 
algorithms we have developed for match testing. 
We first tested whether the assumptions of the model are met in our training 
set. To verify that Hardy-Weinberg equilibrium is present, we determined the fraction 
of SNPs that were homozygous.  If the allele frequency is 50% and Hardy-Weinberg 
equilibrium is present, we would expect 50% of SNP reads to be homozygous.  We 
selected the first allele listed for each SNP in the panel, and determined its 
frequency, which one expected to be 50%.  Note that the other allele will have a 
frequency of one minus this value.  Figure 2 shows the percent of homozygous 
genotypes and the frequency of the first allele, along with the 95% confidence 
interval for the points assuming all assumptions were met.  We observed that neither 
assumption was fully met, since a majority of the points do not fall within the 95% 
confidence interval.  Even though the two assumptions are not met, we tested our 
algorithms to observe the performance. 
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Figure 2: An examination of algorithm assumptions. The percentage of homozygous 
genetypes and allele frequencies for each SNP. Assumptions are not met perfectly, 
but are followed approximately. 
 
Performance of Algorithm 1 for Global Comparison 
First, the training set was used in the development of the scoring scheme for 
the global algorithm.  We used the following criteria to determine the heterozygous 
mismatch score: 
 
1.  The results should match the results obtained by manual review.  
2.  When more than two samples match, the resulting network should be a 
clique (i.e., every specimen matches every other specimen in the group). 
3.  The scores should be bimodal with clear separation between the matching 
and mismatched specimen total scores. 
4.  The heterozygous mismatch score should be as low as possible while 
satisfying the other conditions. 
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Based on these criteria, we incrementally increased heterozygous mismatch 
scores starting with a value of -1 and decreasing it by 1 per iteration.  A value of -1 
was not sufficient, and allowed samples that had been manually determined to be 
from two different patients to have a small number of matches between them.  
These matches violated condition 1, as they did not match in manual review. These 
matches also violated condition 2, because every sample from one patient did not 
match every sample from the other patient, and the group consisting of both 
patients was not a clique in many instances.  We next attempted a value of -2 for 
the heterozygous mismatch score and found all conditions were met. 
When all samples are compared, an extremely small proportion is expected to 
match because there are only a few samples from the same patients.  The mean 
score of all comparisons conducted in our training set (i.e., -114) is only slightly 
higher than the theoretical mismatch score of -135.  Figure 3 is a histogram of all 
pair wise comparison scores in the training set.  We observe that only a single mode 
is visible and all comparisons appear to be non-matches.  This is expected since the 
majority of the non-diseased specimens at the bank are expected to be from 
different donors.  In Figure 4, we show a similar histogram, but only include scores 
greater than 0 so the non-matching mode doesn't dominate.  From this view, we also 
observe a clear separation between the two modes, with the tail of the non-matching 
group on the left and the small number of matches on the right (i.e., matching 
versus non-matching scores).  The mean score for matches (i.e., score ≥ 40) was 
found to be 68.8, which is consistent with the predicted value of 67.5.  Also, the 
predicted threshold of 40 accurately defines a good threshold between the two 
modes in the observed bimodal distribution (Figure 6).  The algorithm identified a 
single pairing that was not previously identified.  Further review by our panel of 
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geneticists determined that the sample pair was indeed a match and the algorithm 
was correct. 
 
Figure 3: Distribution of scores generated by the global algorithm using the training 
data set (n=1504) 
 
 
Figure 4: Distribution of scores greater than zero generated by the global algorithm 
using the training set (n=1504) 
 
The validation set consisted of 1457 samples obtained at NCH during routine 
processing for TCGA.  This number does not include samples with IDs having less 
than 40 SNP calls.  These specimens were quarantined at NCH until all scoring and 
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decision criteria were finalized on the training set.  Using the scores and decision 
criteria obtained from the validation set, we implemented our global comparison 
algorithm on this data set.  We observed a perfect concordance between the 
relationships identified by our algorithm and the relationships that were previously 
identified by geneticists at NCH. Figure 5 and Figure 6 report the same information 
for the validation set as Figure 3 and Figure 4 described for the training set.  
Comparing the validation and training sets, we observed that the distribution of 
scores were nearly identical in both cases.  This indicates that our algorithm for 
global comparison is highly likely to be useful for different data sets.  
 
Figure 5: Distribution of scores generated by the global algorithm using the 
validation set (n=1457). 
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Figure 6: Distribution of scores greater than zero generated by the global algorithm 
using the validation set (n=1457). 
 
Table 2 shows the average results of the three replicates during simulation. It 
should be noted that each of these numbers is from a total of 1.25 billion 
comparisons. It is noted that there is not a major increase the number of marginal 
results until the MAF drops below 30-35%, and false positive results don’t start to 
occur until MAF below 25-30%. Using the individually calculated MAF values (mean = 
0.365, minimum=0.226) for each SNP in our dataset (“Observed”), we find a very 
manageable number of marginal results and no false positive results. 
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Table 2: Marginal and positive results in randomly simulated trials of 50,000 samples 
for various minor allele frequencies. 
   
Performance of Algorithm 2 for Comparison of Diseased and Non-diseased Specimen 
Pairs 
The method for comparing diseased and non-diseased specimen pairs was 
derived without the use of data, thus there is no need for the use of a training set.  
The results from 1504 specimen pairs obtained at IGC during routine processing of 
specimens for TCGA was used for validation.  Since the algorithm is designed for 
hypothesis testing rather than a global comparison to determine specimen 
relationships, we only conducted comparisons on paired diseased and non-diseased 
samples that were believed to come from the same patient.  We validated the model 
by verifying that the results follow the distributions that we identified and have 
provided above.  There is no “absolute truth” available regarding this comparison, as 
all cases in the data set were originally “believed” to match.   
A summary of the results of our tissue matching comparison shows that 
specimen pairs fall into two separate groups:  matching and nonmatching pairs. 
Figure 7 shows the number of matching and nonmatching SNPs present for each of 
the 1504 paired specimens.  A SNP was only counted if the disease-free specimen 
was homozygous for that SNP.  We observe from the figure that there are two clear 
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groups, as expected.  The first group contains 0 or 1 non-match, and an average of 
about 25 matches.  The second group contains many mismatches with a much 
smaller number of matches.  This result is what was expected.  There are three 
comparisons that have 5 to 10 matches and 0 or 1 nonmatches that do not fall into 
the expected groups.  These comparisons were in fact ambiguous to geneticists as 
well.  
 
Figure 7: Mismatching vs. matching SNPs for tissue comparisons. 
 
Discussion 
We have developed two intuitive and efficient algorithms to analyze SNP 
genotypes.  Although the derivation of these algorithms was mathematically 
complex, the actual execution is simple.  The global algorithm assigns a distance 
metric to comparisons in a straightforward manner with simple thresholds to decide 
matching versus nonmatching relationships for the entire database of specimens. 
The algorithm for paired diseased and non-diseased specimen comparisons, on the 
other hand, is designed to overcome genetic abnormalities due to LOH and 
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mathematically assesses the similarity between two specimens using the information 
from a predetermined number of SNPs.  Either of these algorithms can be 
implemented manually or using a worksheet application or script.   
The global comparison algorithm was found to be highly robust in its ability to 
accurately determine specimen relationships de novo even when the assumptions 
were not perfectly met.  In particular, we found that results obtained from the 
validation set matched the distributions obtained from the training set.  The 
threshold value of 40 that we determined and verified in the training set was also 
found to provide effective separation between matching and nonmatching specimens 
in the validation set, as was seen in Figure 8.  All known matching specimens were 
confirmed to match by our algorithm.  Furthermore, the algorithm found a previously 
undiscovered additional set of matching specimen IDs in our training set that was 
confirmed to be a true match after further manual review.  
We observed a small number of cases that were in the region between the 
two modes (match and non-match) in our validation set (Figure 8) that justified 
additional review as no scores fell within this range in our training set (Figure 6).  
Upon review, we found that the one case with a score of 44 (which was deemed to 
be a marginal match according to the identified decision rules) has a simple 
substitution of CC to TT in a single SNP, while all other SNPs matched.  In this case, 
we decided that the marginal match result was actually appropriate, because it 
flagged the result for manual review.  Three comparisons had a score of 36, which 
was just below the threshold for a marginal match.  Manual review of these 
specimens indicated that they did not match; suggesting that the score derived by 
the algorithm correctly categorized these three suspicious points.  The other 
comparisons had scores that fell between 20-30 (clearly within the non-match range) 
were confirmed as being non-matches by subsequent manual review. When results 
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were simulated, we found that our results are fairly robust to assumptions being 
approximately met. It was noted that with the 1000 Genomes data was deposited 
into DBSNP after completion of this study, and one could fairly easily find SNPs that 
match the assumptions in a near perfect manner with minimal effort. 
The algorithm for verifying tissue matching between diseased and non-
diseased specimens was also very robust (Figures 6 to 8).  Of all the comparisons 
conducted, only three results were ambiguous. In this case, there were only 10 SNP 
matches and either zero or one SNP mismatch.  Although this result is possible, it is 
highly unlikely that a result this extreme would be attained by our sampling of about 
1500 cases.  Otherwise, we tended to get more matching SNPs than expected when 
the data is viewed as a whole, which is likely due to the assumptions of the model 
not being met.  Specifically, allele frequencies that are not 50% and alleles that are 
not in Hardy-Weinberg equilibrium would be expected to make more matching alleles 
whether specimens match or do not match. 
One weakness of our approach is that we compared our experimental 
algorithm to the calls made by manual review.  It is conceivable that two specimens 
could have highly similar results and would erroneously be called as a match by our 
algorithm and manual review when they were in fact not matching.  Although our 
model suggests the risk of such an event is trivial, such a possibility cannot be 
eliminated.  Indeed, all specimens used in this study were expected to have known 
relationships, and this study would have been irrelevant had they been correct. 
In general, we observed more matching SNPs than were expected for both 
matching and non-matching specimen comparisons for both algorithms.  Again, this 
is most likely caused by some assumptions not being completely satisfied.  While it is 
possible to modify our methods to match the data distribution exactly, it would 
defeat our main goal of developing a simple, intuitive and efficient algorithm. 
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Verifying specimen relationships is an important quality control process for 
biobanking. However, no simple, automated and high-throughput data analysis tools 
are commonly available.  In this study, we provided two algorithms that establish 
specimen relationships, which can be customized to evaluate results from a variety 
of SNP assays.  The first algorithm provides a global comparison of all specimens in 
the database and is highly suitable for identification of unexpected sample 
duplication.  The second algorithm is tailored for tissue matching between diseased 
and corresponding non-diseased tissue that is complicated by LOH.  Both algorithms 
provide rapid and easily interpretable results and can be performed on a common 
laptop computer.  These algorithms are important for automating error detection in 
sample IDs that could otherwise compromise the quality and effectiveness of 
downstream processes.   Moving forward we hope the integrity and reliability of the 
biobanking industry is improved by use of quality control tools such as described 
here.   
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CHAPTER 3 
OPTIMAL HIGH DENSITY MULTIPLEXING OF QUANTITATIVE PCR 
 
Abstract 
Aims: It is highly desirable to multiplex PCR reactions, especially ones that 
are already validated individually.   It is rarely possible to multiplex large numbers of 
PCR reactions by trial-and-error methods due to the large number of combinations 
possible. Methods: We identify and quantify the consequences of phenomena that 
cause conflicts between multiplexed PCR reactions, and use an integer programming 
model to partition existing qPCR reactions into multiplexes while minimizing conflicts. 
Results: We simulated a variety of scenarios, and determined that it was feasible to 
multiplex many assays into a small number of multiplexes even when extremely high 
dimer conflicts existed. For a case study, we used two sets of reactions, one 
contained 56 quantitative PCR (qPCR) reactions for RNA and one contained 86 DNA 
assays. The RNAs were successfully multiplexed into four multiplexes with an 
average of 14 reactions per multiplex, and the DNAs were successfully multiplexed 
into four multiplexes with and average of 21.5 reactions per multiplex. Conclusion: 
We provide a reliable method for multiplexing existing quantitative PCR assays into a 
small number of multiplexes. We determined a method to successfully multiplex PCR 
reactions while reducing the relative abundance of dimers to desired PCR product. 
 
Introduction 
Multiplexed PCR is highly desirable because it allows multiple PCR assays to 
be run in a single tube (Henegariu 1997) (Edwards 1994). When multiple PCR assays 
are multiplexed, the primers for all assays are put into the same tube, and each 
target is amplified independently of the others simultaneously. This reduces assay 
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setup complexity by reducing the number of reactions run, which leads to reduced 
costs and consumption of the sample being analyzed. The main limit of multiplexing 
has been the ability to analyze the results for each reaction separately until recently. 
For example, when samples are analyzed by gel electrophoresis, the main limit is the 
number of fragments that can be resolved from each other on a gel (Edwards 1994). 
Taqman probes allow the amplification level of each reaction to be monitored in real-
time via fluorescence (Life Technologies 2013), but this process is typically limited to 
four reactions per multiplex due to limitations on the number of fluoresce markers 
that can be distinguished (Applied Biosystems 2013). With the widespread 
deployment of next-gen sequencing methods (Schuster 2007) (Bybee 2011), it is 
now possible to individually sequence DNA strands, making it possible to identify 
each DNA molecule individually with near perfect accuracy. This allows a near 
unlimited number of molecules to be distinguished.  
A method to multiplex very high numbers of molecules is highly desirable.  
However, this cannot be accomplished by simply putting many PCR assays into a 
single tube. When one attempts this, there is a high probability that dimers will form 
(Brownie 1997). Because these dimers occur in a template-independent manner and 
primers are present at concentrations many orders of magnitude greater than 
template, they rapidly outcompete the intended reaction. It is fairly straightforward 
to predict whether a given pair of reactions will generate dimers (Figure 8). We 
noted two types of dimers: amplifiable ones that are amplified during the PCR 
reaction, rendering the entire assay useless by consuming the reaction components, 
and non-amplifiable ones that cause a lesser loss in quality by rendering fewer 
primers available to prime template. It should be noted that DNA polymerases used 
in PCR can only extend DNA in a 5’-3’ direction, and this is the primary distinction 
between an amplifiable and non-amplifiable dimer. 
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Figure 8: Illustration of amplifiable dimers (top) and non-amplifiable dimers 
(bottom). Note that the amplifiable dimer can be extended in the 5’-3’ direction, but 
the non-amplifiable dimer cannot. 
 
Previous work focuses on making multiple assays distinguishable from each 
other (Rachlin, 2005; Konwar, 2005). Previously, gel electrophoresis was used to 
discriminate between amplicons, which can only discriminate between different sizes 
of PCR products. Neither of these studies attempted, however, to prevent the 
formation of dimers. Thus, the goal of these projects was to create PCR reactions of 
various sizes that could be easily discriminated by electrophoresis. It is likely that 
dimers did not present a major issue as the number of assays multiplexed was fairly 
small. Additionally, dimers were probably not a major issue as they do not resolve 
well on the types of gels used in this study, thus they could be readily ignored. 
Fortunately, designing assays to allow separation on gel electrophoresis is no longer 
necessary with modern next-gen sequencing technologies, as the identity of PCR 
products can be obtained directly from the sequence result regardless of the PCR 
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reaction size. Additionally, the types of assays being optimized in these studies 
involved a qualitative outcome: either a PCR fragment was present, or it wasn’t. It 
was not necessary to measure fragments in a quantitative fashion, or in other terms, 
preserving relative differences between different amplicons. In order to accomplish 
this, these studies generated many sets of primers in silico, and then determined 
which ones work best together. 
Another method described by Shen et al. (Shen 2010) focuses on minimizing 
the formation of dimers. Much like our team, the authors observed the negative 
impact of dimers and the need to prevent their formation during PCR. They 
generated many primers for each target region, and then selected a subset that 
would not conflict with each other in a single reaction. A greedy graph-expanding 
algorithm was used.  In many regards, this is the work most similar to ours. It is 
different in the respect that it focuses on creating many assays and selecting only 
those that are compatible rather that our strategy of multiplexing existing assays 
without excluding any. 
Our proposed method provides three clear advantages over the state-of-the-
art. First, it allows us to handle the two types of dimers (amplifiable and non-
amplifiable) separately. This is desirable because amplifiable dimers cause 
substantially more issues than non-amplifiable ones and thus it may be desirable to 
allow several non-amplifiable dimers rather than accepting a single amplifiable one.  
Second, it allows the use of existing assays that have already been validated. This 
allows conversion of legacy PCR assays to next-gen sequencing multiplexes, and also 
overcomes the recurring issue that only 80-90% of RNA assays will work on difficult 
specimens by allowing all assays to be individually designed and validated prior to 
multiplexing. Third, it allows a group of existing PCR assays to be partitioned into 
multiple multiplexes. This may be desirable when there is a conflict between two 
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required assays that prevents them from being run in the same multiplex or when 
there is a limit on the maximum number of assays per multiplex. 
 
Methods 
Our goal is to organize a set of PCR reactions into a pre-defined number of 
multiplexes. This organization must prevent any two assays that would form an 
amplifiable dimer from being put in the same multiplex. The grouping of PCR 
reactions must also minimize the sum of the non-amplifiable pairwise dimers present 
in each multiplex. We assume that dimers only form in a pairwise manner between 
assays. We do not anticipate or assume that higher order dimers will occur. For 
example, we assume that putting three assays into a multiplex will not cause a dimer 
to form if none of the three possible pairings of results in a dimer. Additionally, we 
want to limit the total number of assays present in each multiplex to a pre-defined 
number to control the depth of multiplexing. Unlike other methods, we only focus on 
existing primer sets, and do not make attempts during oligo design to minimize the 
risk of dimers forming between different reactions. 
 
We define an integer program as follows: 
Parameters: 𝑁 ∈ 𝑍! ∶=   the  number  of  assays  to  be  multiplexed 𝑛 ∈ 𝑍! ∶=   the  maximum  number  of  assays  to  be  put  in  one  multiplex 𝑀 ∈ 𝑍! ∶=   the  number  of  groups  (multiplexes) 
 
We define the decision variable, 𝑥!" ≔ 1 if assay 𝑖 is in group 𝑗 and 𝑥!" ≔ 0 
otherwise, for all 𝑖 ∈ 𝐼 and 𝑗 ∈ 𝐽. Note that we use the term “group” here to represent 
a subset of assays multiplexed together into a single reaction. 
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We define the first constraint to ensure each assay is assigned to one and 
only one group: 
 𝑥!" = 1  !∈!    for all 𝑖 ∈ 𝐼 
Equation 1 
 
We next define a constraint to ensure that no more than n assays are 
assigned to any group: 
 
𝑥!" ≤ 𝑛        for  all  𝑗 ∈ 𝐽!∈!  
Equation 2 
 
Note that it was previously stated that amplifiable dimers were not allowed 
within a multiplex. Rather than writing a constraint to prevent this, we instead 
penalize this occurrence in the objective function. In order to assign penalties to 
pairings of assays, we need to define a new binary variable. We let 𝑦!"# = 1  if 𝑖 and 𝑘 
are both in group 𝑗, and 𝑦!"# = 0 otherwise, for all 𝑖, 𝑘 ∈ 𝐼 and  𝑗 ∈ 𝐽. We write the 
constraint as: 
 𝑦!"# ≥ 𝑥!" + 𝑥!" − 1,                for  all  𝑗 ∈ 𝐽,        𝑖, 𝑗 ∈ 𝐼, 𝑖 ≠ 𝑘 
Equation 3 
 
We assume that a penalty matrix 𝑅!×! provides the penalty of putting 
reactions 𝑖 and 𝑘 together, with each element being 𝑟!". If putting reactions 𝑖 and 𝑘 
together does not result in any amplifiable or non-amplifiable dimers, then 𝑟!" is set 
to 0. If there is a non-amplifiable dimer, then 𝑟!" is set to an arbitrary value of 1 to 
slightly penalize this undesirable situation. If there is an amplifiable dimer, on the 
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other hand, 𝑟!" is set to a large number, for example 𝑁!, to ensure that it is always 
preferable to eliminate one amplifiable dimer over any number of non-amplifiable 
dimers. Finally, we write the mathematical programming formulation as: 
 
minimize 𝑟!"𝑦!"#!!!!∈!!∈!  
Subject to:  𝑥!" = 1          for  all  𝑖 ∈ 𝐼  !∈!     𝑥!" ≤ 𝑛        for  all  𝑗 ∈ 𝐽!∈!  𝑦!"# ≥ 𝑥!" + 𝑥!" − 1,                for  all  𝑗 ∈ 𝐽,        𝑖, 𝑘 ∈ 𝐼, 𝑖 ≠ 𝑘 𝑥!" ∈ {0,1}            for  all  𝑖 ∈ 𝐼, 𝑗 ∈ 𝐽 𝑦!"# ∈ {0,1}          for  all  𝑖, 𝑘 ∈ 𝐼, 𝑗 ∈ 𝐽 
 
Equation 6 
 
This problem was coded into OPL and was solved with CPLEX (IBM, Armonk, 
New York). We optimized multiple problem instances involving the partitioning og 
60-80 reactions into four groups, and the runtime was typically 1 second to 15 
minutes on a single 2.4gHz core system with 4GB memory available on Windows 7. 
These problems were all real problems being solved, and thus, are a good sample of 
problems likely to be experienced in the future.  
 
Determining the optimal number of multiplexes 
Rather than specifying a value of 𝑁, the number of multiplexes, in advance, 
one may wish to optimize this value. Lower values of 𝑁 result in less work in the lab 
each time the assay is run, but higher values of 𝑁 may have the advantage of 
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resulting in less dimers. There is no direct method to quantify the trade-off between 
number of multiplexes and the amount of resultant dimers. It was assumed that 
even one amplifiable dimer was unacceptable, but non-amplifiable dimers may be 
tolerable.  
In order to facilitate decision-making, we create a chart showing the trade-off 
between the number of multiplexes and the number of dimers. It describes the best 
possible solution for each value of 𝑁. If we set the penalty for an amplifiable dimer to 𝑁!, we can ensure that a higher priority is put on removing amplifiable dimers than 
non-amplifiable ones. From a given value of the objective function, 𝑍∗, we can 
determine exactly how many amplifiable 𝑍∗/𝑁!  and non-amplifiable dimers 
(𝑍∗  mod  𝑁!) are present based on each objective value, where mod is the modulo 
operator. 
In order to determine the trade-off, we need to explore three criteria. Each of 
these values may be determined readily.  
• The number of multiplexes, 𝑁 
• Amplifiable dimers, 𝑍∗/𝑁!  
• Non-amplifiable dimers, 𝑍∗  mod  𝑁! 
 
For example, if 𝑁 = 5 and we obtain 𝑍∗ = 58, we can determine that there are two 
amplifiable dimers and 8 non-amplifiable dimers in this problem. 
To simplify somewhat, we can state that there must never be any amplifiable 
dimers, so the first feasible value of 𝑁 is the lowest value for which there are no 
amplifiable dimers. At this point, we need to decide on the tradeoff between non-
amplifiable dimers and number of multiplexes. For larger problems, these results 
could be plotted as shown in Figure 9. This chart allows the scientist to observe the 
trade-off between dimers and the number of multiplexes. This also provides an 
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important secondary function of allowing the scientist to make the final decision 
based on observation of the results, which is critical for acceptance. This provides 
additional utility as scientists are trained to scrutinize results to make a decision and 
are unlikely to trust a method that gave a solution they could not review. 
 
 
Figure 9: Mock-up of dimers vs. Multiplexes chart. This chart shows how adjusting 
the number of mulitplexes affects the number of dimers. The dotted line shows the 
value where no amplifiable dimers are present. 
Simulation 
In order to understand the effects of various parameters on the performance 
of this multiplexing strategy, we simulated various penalty matrices, 𝑹. Many 
scenarios were studied, but the most valuable studies were the ones where 𝑹 
matrices were randomly generated, with a given probability that any given pair of 
reactions would cause a dimer. The number of assays to be multiplexed was varied. 
In each case, the number of multiplexes to be created was varied as shown in Figure 
9. 
For the first simulation, a total of 100 assays were multiplexed. Rather than 
simulating primer sequences, we simulated the values of the penalty matrix, 𝑹. In 
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real-world scenerios, this is a deterministic process as the primer sequences are 
defined, and generating the penalty matrix is a deterministic process. For simulation 
purposes, we selected 10% probability that any given pair would result in an 
amplifiable dimer, and a 10% chance it would result in an non-amplifiable dimer. The 
variance parameter, 𝒒, was set to 10%. The results are shown in Figure 10. In this 
example, amplifiable dimers were eliminated with 8 multiplexes, and all dimers were 
eliminated by 10 multiplexes. It was noted that the number of amplifiable dimers 
was non-increasing with respect to the number of multiplexes, but the number of 
non-amplifiable dimers was not. This is because an amplifiable dimer is penalized 
substantially higher than a non-amplifiable one, and there are scenarios where 
allowing several dozen non-amplifiable dimers would allow elimination of an 
amplifiable one. In this case, the objective function is still non-increasing. 
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Figure 10: Plot of multiplexes vs. dimers for a simulated scenario involving 100 
reactions where the rate of amplifiable and non-amplifiable dimers is 10%. 
 
The same situation was simulated again, with the rate of both non-amplifiable 
and amplifiable dimers decreased to 5%. The result is shown in Figure 11.  As 
expected, the number of multiplexes required is lower, with only 5 being needed to 
remove amplifiable dimers and 6 being needed to remove all dimers. 
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Figure 11: Plot of multiplexes vs. dimers for a simulated scenario involving 100 
reactions where the rate of amplifiable and non-amplifiable dimers is 5%. 
 
The same situation was simulated again, with the rate of both non-amplifiable 
and amplifiable dimers increased to 15%. At this point, the situation is so extreme it 
is beyond what would be experienced in any realistic scenario with a total of 30% of 
pairings generating a dimer of some type. The result is shown in Figure 12.  As 
expected, the number of multiplexes required is higher, with 10 being needed to 
remove amplifiable dimers and 14 being needed to remove all dimers. This is still 
fairly low considering that many consider it difficult to multiplex even 4 assays into a 
single reaction. If we only attempt to remove only amplifiable dimers, we can still 
average 10 assays per multiplex even with a 15% amplifiable dimer rate. 
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Figure 12: Plot of multiplexes vs. dimers for a simulated scenario involving 100 
reactions where the rate of amplifiable and non-amplifiable dimers is 15%. 
 
Case Study 
In order to verify the effectiveness of this method with respect to its stated 
purpose of creating multiplexed PCR assays without interfering dimers, we created 
PCR assays, verified them, designed a multiplex strategy with the method outlined, 
then ran the obtained PCR assay to verify dimers were not present. Primers were 
designed using RealTimeDesign software (Biosearch Technologies 2014). Each 
primer pair was synthetized and run through a variety of tests to verify it met the 
quality metrics individually. Reactions were re-designed as needed. Dimers were 
detected via AutoDimer software (Butler 2004), and a program was written to insert 
the AutoDimer results into the penalty matrix used by the optimization program. In 
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brief, this program parses the output from AutoDimer, determines which assays are 
involved in each dimer, determines whether the dimer is amplifiable or not, then 
outputs the penalty matrix, 𝑹, in a format that can be readily read by OPL. 
In order to demonstrate the improvement obtained with our method, we 
started by arbitrarily multiplexing primers into two groups as a non-optimized 
method. This process was conducted in the laboratory and not in silico. This attempt 
was conducted before we understood how severely dimers affected our process, and 
only one attempt was conducted as it was immediately clear how poorly multiplexing 
performed when the grouping of the reactions was done arbitrarily. Figure 13 shows 
the results of this experiment. It is clear to a molecular biologist that the majority of 
product present is dimer, especially in the second multiplex where almost no true 
amplicon is present. One can observe the dimers in as the shorter fragments in the 
region indicated by “dimer” and the true PCR product as the longer fragments in the 
region above the top blue line. These were next-gen sequenced, but little meaningful 
data were obtained, as nearly all reads were the unwanted dimer products. 
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Figure 13: Non-optimally multiplexed PCR. Two multiplexes (1,2) run. +/- indicates 
whether positive control (with template) or negative control (no template). RT+/RT- 
indicates whether reverse transcriptase was added. Different multiplexes are run on 
the horizontal axis, and the direction of the electrophoresis is from the top to the 
bottom, such that smaller fragments appear lower on the gel. The smallest band on 
the ladder is 50bp, and the second is 100 bp. Dimers appear as small fragments 
between the two blue lines. Based on this figure, it is clear that nearly all product of 
the reaction is dimer. 
 
We then used our optimization method to multiplex the reactions, and 
sequenced them using a custom Ampliseq panel on Ion Torrent PGM. Two reactions 
had to be removed after viewing results. Two reactions caused an apparent single-
primer dimer, which likely occurred during the emulsification PCR step and thus 
would not be captured by our method.  
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Figure 14: Comparison of read length with random multiplexing (left) and 
multiplexing via the discussed method (right). Dimers are less than 50bp long, and 
amplicon is larger than 50bp. With random multiplexing, nearly all reads are dimer, 
while less than 5% of the reads are dimer after using the discussed method.  
 
After using our multiplexing method, no dimers were visible by gel (Figure 
14). When the same set of primers were randomly assigned to groups and 
sequenced on the Ion Torrent PGM, nearly all reads were dimer. Dimers can be 
readily identified by size alone as it is impossible for a dimer to be larger than 50 bp, 
and it is impossible for amplicon to be smaller than 50bp. 
 
Discussion 
We have successfully modeled risk of primer dimer formation and developed a 
model to prevent their formation during multiplexing. This model was tested in a 
case study and performed well. Our method is unique in two regards. First, it 
multiplexes existing assays rather than creating new ones. This allows easier 
multiplexing of assays that are difficult to create, because it is known in advance that 
the assays are able to detect their target prior to multiplexing. Second, we focus on 
preventing dimer formation. Unlike other methods, next-gen sequencing is 
particularly sensitive to dimers. Preventing dimer formation substantially increases 
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the number of usable reads by reducing the number of unusable dimer reads. Our 
method provides an effective solution to an emerging problem. 
The use of an integer program substantially decreases the required effort 
when compared to enumeration of all possible solutions. In the example of 100 
assays being multiplexed into 4 multiplexes of 25 reactions each, a total of 𝟏𝟎𝟎𝟐𝟓 𝟕𝟓𝟓𝟎 𝟓𝟎𝟐𝟓 = 𝟏.𝟔×𝟏𝟎𝟓𝟕 possible combinations exist. The world’s most powerful 
computer, Tianhe-2, is capable of 38.86 petaflops/s. Using this computer, it would 
take 𝟏.𝟑×𝟏𝟎𝟑𝟓 years. 
The ability to multiplex existing assays is very valuable for those planning to 
convert existing assays from legacy analysis methods to next-gen sequencing. For 
example, Genomic Health may benefit by converting their Oncotype Dx panel to a 
next-gen sequencing assay by this method. This method is also useful for those 
designing particularly difficult assays that are unlikely to work on the first attempt. 
For example, Paradigm Diagnostics and Viomics use this method to multiplex 
complex RNA assays that only have an 80% success rate. This allows assays to be 
optimized individually, then multiplexed. A third use of this method is to multiplex 
assays where only a small number of possible designs work for a given target. For 
example, certain mutations may only be targeted by a single assay design, so 
methods that design many assays until they find one that can readily be added to a 
multiplex are not useful. Paradigm Diagnostics uses this multiplexing strategy for 
this purpose. 
This strategy relies upon an integer program, which typically produces a 
single, unique solution; however, in this case, a series of solutions are produced, 
allowing the researcher to select the one that best fits their situation. It is hard to 
anticipate all factors that will influence the day-to-day use of an assay, and scientists 
generally like to be involved in this decision-making process. For example, a machine 
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may run 96 reactions at a time in a PCR plate with 8 rows and 12 columns. In this 
case, a researcher given the option between seven or eight multiplexes may select 
eight because it allows each patient to have a full row in the PCR plate. Paradigm 
Diagnostics uses the Rotor-Gene Q instrument (Qiagen), which runs tubes that come 
in sets of four, so four multiplexes are preferred. All such circumstances cannot be 
anticipated in advance, and the plot of multiplexes vs. dimers provides a valuable 
tool for decision making by experts. 
In conclusion, we have developed a method to multiplex existing PCR assays 
without creating dimers. This method is proven experimentally to substantially 
decrease the number of dimers present while increasing the relative proportion of 
usable reads. 
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CHAPTER 4 
ROBUST NORMALIZATION OF MULTIPLEXED QUANTITATIVE MOLECULE COUNTING 
ASSAYS AGAINST A KNOWN REFERENCE RANGE  
 
Abstract 
We created a method to normalize gene expression and copy number results 
obtained from next-generation sequencing (NGS) that is suitable for medical 
diagnostics. The method allows direct comparison of a patient specimen to a small 
collection of similar but disease-free tissues. A robust normalization method scales a 
new sample in such a way that it can be directly compared to the reference range by 
eliminating certain competitive effects that are unique within NGS. Unlike other 
methods, ours does not require subjective tuning of parameters. This method allows 
robust normalization of samples with high levels of expression alteration, and from 
samples that are highly degraded. This method was tested via simulation and is used 
by Paradigm Diagnostics, inc. for analyzing patients in their PCDx test. 
 
Introduction 
One of the most difficult computational tasks in modern molecular biology is 
converting RNA expression data into meaningful and useful data (Schlitt 2004). 
When microarrays, the first major such technology, were introduced, a full 
understanding and subsequent cure of cancer appeared eminent (Perez-Diez 2000). 
However, it rapidly became evident that these results required a different type of 
analysis compared to other biological results (Allison 2006; Ioannidis 2009). The field 
of bioinformatics rapidly developed around these new assays, but tended to focus 
primarily on datamining-type techniques such as clustering (e.g., K-means) rather 
than statistical methods (Allison 2006).  
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By the time of this writing, a wide variety of biomarkers that can predict 
response to a particular treatment are known (Von Hoff 2010). Most of these 
markers were not discovered by meticulous mining of well-curated datasets, but 
rather by deliberately designing completely new types of pharmaceuticals that target 
known biomarkers (Moulder 2001; Baselga 2001; Abe 1998). For example, it has 
long been known that estrogen receptor is present at elevated levels in some 
cancers, leading them to be excessively sensitive to estrogen (Jensen 1971). 
Because estrogen is a growth factor, this stimulated cells to proliferate. The drug 
tamoxifen was developed to block the estrogen receptors, and thus halt the growth 
of tumors fueled by estrogen receptors, but was completely ineffective against 
tumors driven by other factors (Abe 1998). 
The field of targeted medicine (a.k.a. precision medicine) involves screening 
patients for factors known to predict drug response prior to treatment (Von Hoff 
2010). This field focuses primarily on oncology due to the severe side effects of the 
drugs and the limited remaining expected. In other forms of medicine, a trial-and-
error approach to trying different drugs may still be the norm. Tests to predict 
treatment response may involve administering a single test for a single drug (e.g., 
testing for KRAS mutations prior to administering cetuximab) (Baselga 2001), a 
cancer-specific panel of a few tests (e.g., ER/PR/HER2 for breast cancer) (Bauer 
2007), or a large panel that involves hundreds of markers broadly suited for many 
cancer types (Von Hoff 2010). Many scientists have conducted small-scale tests for a 
small subset of these markers, and these tests are often effective for a given cancer 
(Baselga 2001). Few have attempted studies that utilize broad-scale panels (Mook 
2007), and even fewer have designed panels that can be used in a number of 
different cancers (Von Hoff 2010). Such a panel is highly desirable for a person who 
has exhausted all options for their cancer, especially if it is an uncommon cancer. 
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Such a panel may discover a treatment that is known to be effective against a 
marker found in the patient’s tumor but is typically used on a different cancer type. 
For example, ERBB2 gene amplifications are occasionally found in testicular cancer 
(unpublished results), and the drug Herceptin is known to be effective against breast 
cancers with ERBB2 amplification (Bauer 2007). 
In this study, we aim to analyze a broad-scale panel containing a diverse set 
of nucleic acid biomarkers that is relevant to multiple types of cancer. This panel will 
measure four main types of nucleic acid events: mutations, mRNA expression, DNA 
copy number, and chromosomal abnormalities (i.e., gene fusions). This current study 
will only focus on the mRNA expression and DNA copy number components. This 
collection of assays will have higher depth (with respect to the total number of 
markers) and breadth (with respect to the types of markers) than most tests 
currently available. The primary goal of using a broad panel is to maximize the 
probability that an actionable marker will be found. For our purposes, we define 
“actionable” to be a marker that allows clinical intervention with the intent of 
extending life or improving quality of life. 
This type of test has unique design features that are different than those 
found in typical tests. Specificity, or 1 minus the type I error, is very important in a 
test of this type. Patients usually have little time left to live and the drugs have 
major side effects. The drugs recommended are also extremely expensive. The risk 
of finding at least one false positive is increased when compared to a test that 
examines a single marker due to the multiple comparison problem. It is essential 
that the Positive Predictive Value (PPV), or the proportion of positive calls that are 
true positives, of the test is also high. It is acceptable to have a fairly poor sensitivity 
(i.e., 1 minus the type II error).  Poor sensitivity is acceptable as the current option 
of doing nothing effectively has 0% sensitivity; and hence, any level of sensitivity is 
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considered to be an improvement over the current state of medicine. This is 
especially true in RNA expression, where no other alternative is available. In the case 
of DNA mutation (not the focus of this paper), other sensitive methods exist so a 
higher level of sensitivity is required. The goal of this analysis is not to be perfect, 
but rather to present patients and their physicians with a better option than what is 
currently available. 
In expression analysis, and to a lesser extent, DNA copy number analysis, 
changes in relative quantities can be substantial- for example, it is not uncommon 
for a gene to be expressed in amounts hundreds of fold higher in a tumor specimen 
than in a cancer-free one (Gordon 2002, Notterman 2001). These outliers consume 
sequencing wells and suppress reads from other genes. Because there are a finite 
number of wells for detection within the sequencing chip, we are effectively 
measuring contrasts. This concern was first reported and addressed by Robinson and 
Oshlack (2010). For example, suppose we have two genes, Gene 1 and Gene 2 
(Figure 15). If Gene 2 is over expressed and Gene 1 remains constant, it will appear 
that Gene 2 is more prolific and Gene 1 is less prolific because the higher numbers of 
Gene 2 compete with Gene 1 for sequencing wells, leading to a downward ”shift” in 
Gene 1.  
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Figure 15: Overexpression on gene 2 causes apparent decrease in the detected 
levels (left) gene 1 in a cancer patient. Actual values are shown in circles, observed 
values are shown in star shapes.  
 
To explain this further, we again examine Figure 15. This figure shows a 
reference sample that has equal amounts of gene 1 and gene 2 in each cell (circle on 
left), leading to equal amounts observed in sequencing (star shape on right). 
However, when the same process is run on a cancer cell (bottom of figure), which 
has increased expression of gene 2, it leads to an apparent reduction in gene 1 by 
overcrowding the sequencing wells (in this example, there are only a total of 10,000 
sequencing wells present). In this situation, we can multiply the 909 counts of gene 
1 by 5.5 to get the corrected value of 5000. Likewise, for gene 2, we can multiply 
the observed 9091 counts by 5.5 to get a corrected value of 50,000 counts. When 
compared to the reference sample, we can see that gene 1 expression is not altered 
(5000 vs. 5000 counts), but gene 2 has experienced a 10-fold increase in expression 
(50,000 counts in cancer vs. 5000 counts in the reference). Ascertaining the 
multiplier needed to normalize the result is the primary topic of this study. 
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As more genes are available, the effect and a solution become more obvious. 
Figure 16 contains both a “normal” specimen, which does not experience alterations, 
and a “cancer” specimen, which contains one overexpressed gene. This picture 
assumes that 1000 reads are sampled from each specimen, and that there is no 
variance. The “true” value is some representation of the actual number of molecules 
in the specimen, and the “reads” value is what is observed from sequencing. These 
assumptions are not realistic but simplify interpretation. It is clear that all of the 
genes that are not overexpressed are decreased to about 1/4 their original 
expression. If one knew the “true” number of genes, correcting for this would be 
trivial. However, this information is not available in real-world situations. Rather, the 
sampled data must be examined. One could look at each read in the cancer sample 
to determine which number it must be multiplied by to equal the normal read. In this 
case, one would obtain: 3.7, 4.0, 4.0, 4.0, 0.2. It is clear that 4 is the correct 
number, and 0.2 is the outlier. Using a robust loss function achieves the same 
purpose: it looks for groups of genes for which a similar multiplier is ideal. We 
explore various types of loss functions throughout this paper to determine how 
different loss functions affect the ability to normalize. 
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Figure 16: Example of the effects of an overexpressed gene in a five-gene panel. The 
top “normal” sample contains no overexpression, and the bottom “cancer” sample 
has overexpression of gene 5. In this simple example, there is no variance and the 
“reads” results are the ones obtained by sequencing. Multiplying the sampled result 
in the cancer sample by 4 corrects for competition by the overexpressed gene. 
 
 This can also be viewed as a robust regression problem (Figure 17). For this 
type of problem, we are trying to determine the slope with a known zero intercept. 
In this instance, the standard least squares method is influenced heavily by the 
outlier as expected, leading to a substantial difference between the slope estimated 
and the known correct value. It is clear that, if robust regression were conducted 
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with a suitable loss function, the resulting slope estimate would be more accurate 
than the least squares answer. 
 
Figure 17: Sample results of a tumor and normal specimen drawn as a regression 
problem. The solid line represents the known correct solution, and the dotted line 
represents the solution obtained by standard least squared regression with an 
intercept of 0. This is the same data shown in Figure 16. 
 
When NGS first arrived on the market, new algorithms to analyze the 
expression data they generated were not immediately available. As a result, many 
turned to methods designed for microarray. These include Lowess normalization 
(Yang 2002) and quantile normalization (Irizarry 2003). However, microarray is 
substantially different from next-gen sequencing when it comes to measuring 
expression. In microarray, each gene can be read individually. Thus, the competitive 
effects observed in next-gen sequencing are not a concern. 
The reads per kilobase per million mapped (RPKM) method (Wagner 2012) 
was one of the first methods designed specifically for next-gen sequencing. It is 
often still used on NGS data for its simplicity- basically, the number of reads 
obtained for a given gene are divided by the total number of reads obtained. RPKM 
makes no effort to compensate for competitive effects. This method works 
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reasonably well for large panels (for example, 20,000 genes) where only a few 
hundred experience altered expression levels, because the number of altered genes 
is very small in comparison to the number of unaltered genes, and thus, they don’t 
occupy enough sequencing wells to alter apparent gene expression of others 
substantially. 
Robinson & Oshlack (2010) proposed the Trimmed Mean of M values (TMM) 
normalization method to overcome this. They assumed that the majority of genes 
are not differentially expressed. They log transformed data to decrease variance, 
especially from very high values. They then compared gene ratios between a new 
specimen and a reference, removing the upper and lower x% of the ratios. Using the 
remaining data, they estimated a scaling factor that can be used to adjust a sample 
to align it to the reference. 
The state of the art in this field is tailored to large-scale research projects. 
Our aim in this project is to design a method that is useful in real-world clinical 
situations. Medical diagnostics typically focus on small subsets of genes (20 to 200) 
that are expected to have altered expression. In these cases, the assumption that 
the vast majority of genes will be unaltered is not valid. Unlike the TMM, we don’t 
need to identify genes with altered expression, nor do we need to assume that the 
majority of genes are not altered. Our only assumptions are: 1) when genes 
experience altered expression, the magnitude of expression alteration is independent 
for each altered gene and 2) there is a subset of genes that are not altered. While 
our method does assume that there are unaltered genes that can be used for 
normalization, it does not have hard limits on what proportion of genes are unaltered 
nor does it require identification and exclusion of altered ones. Our proposed method 
also accounts for variance in gene expression in addition to the mean, providing a 
model of greater fidelity to describe this complex process. 
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Methods 
We want to develop a method to analyze next-gen sequencing data that will 
allow normalization and identification of significant events in both RNA and copy 
number. We assume that DNA library construction (copy number and mutation) is 
independent of RNA library construction (expression). We additionally assume that 
each library made from RNA is independent of the other RNA libraries, and thus, 
must be normalized separately. 
Our primary goal in this normalization process is to center the data correctly 
without the need to identify outliers (i.e., genes that experience significant 
alterations upward or downward in expression). As shown in Figure 15, once the 
scaling factor is known, one can simply multiply the expression results by this 
number to get the data adjusted so that it can be directly compared to the values 
obtained in cancer-free tissues. Thus, we want to use a loss function that focuses on 
groups of values that are similar to cancer-free tissues and tends to ignore extreme 
values. This is effectively the opposite of the standard least squares loss function, 
which puts high weight on extreme points.  
We calculate 𝒂 as the input that yields the minimum value over a loss function 
(see example in Figure 16 above). The loss function yields a value that estimates 
how well a given value of 𝒂 serves to align a cancer specimen to a previously 
determined reference range. A well-selected loss function will have a high probability 
of yielding a minimum at the correct value of 𝒂. While the correct value of 𝒂 is 
usually not known in advance, simulated data based on known values can be used to 
determine the accuracy of different loss functions. Additionally, paired samples 
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handled in different ways can be sequenced and normalized by a given loss function, 
with correlation of the final result being a measure of loss function accuracy. 
Although these loss functions are typically not convex, our method only 
requires finding a minimum over a single parameter with a narrow range of values. 
Indeed, a value of 𝒂 less than one would imply that genes experienced decreased 
expression. After running over 100 actual cases, it became apparent that values of 𝒂 
greater than five are not observed. Thus, simply enumerating values over a given 
range, for example between 0.5 and 5 with increments of 0.01, can be done within a 
second on a modern computer. 
This is a novel method for comparing one sample to a reference range while 
being robust to outliers. In this application, outliers are the most interesting results, 
so a method that allows normalization in their presence is highly desirable. This 
method does not require the comparison of results to additional pre-defined 
reference genes under the (often false) assumption that the reference genes are not 
altered. Once normalization is complete, standard statistical tests can be done, such 
as a t-test, to determine if individual genes are altered.  
 
Derivation of loss function 
We want to find the value of 𝒂, a scalar multiple that corrects for well 
competition, i.e., the apparent decrease in reads in response to an overexpressed 
gene. To generate a custom loss function, we start with a logistic function (Equation 
1). This function was selected because it is robust to outliers, i.e., it gives higher 
weight to groups of data points that are similar and lower weight to individual outlier 
points. For now, we only assume that 𝒙 is related to 𝒂. The exact nature of this 
relationship will be explored later. 
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𝒇 𝒙 = 𝟏𝟏 + 𝒆!𝒙 
 
Equation 1 
We then subtract ½ and square the function to make it two-tailed (Equation 
2). This is necessary to penalize both overestimation and underestimation of 𝒙. 
𝒇 𝒙 = 𝟏𝟏 + 𝒆!𝒙 − 𝟏𝟐 𝟐 
 
Equation 2 
The plots of the two functions can be seen in Figure 18. It is clear that 
modifying the function in this way converts a one-tailed function to a two-tailed one. 
We also note that as the value of x moves away from zero, the slope of the line 
approaches zero. This tendency gives less weight to extreme points when we use 
this as a loss function. 
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Figure 18: Logistic function (top) and the modified function created by subtracting 
1/2 then squaring the logistic function (bottom). 
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We then make a few modifications to make this function work in this 
application. We define the following parameters: 𝒎 ≔ The number of genes in the panel 𝑰 = 𝟏,𝟐,…𝒎 ≔  The set of genes in the panel 𝝁𝒊 ≔ Estimated mean expression from the reference range 𝝈𝒊 ≔ Estimated standard deviation of expression from the reference range 𝒙 = 𝒙𝟏,𝒙𝟐,… ,𝒙𝒎 ≔ An array of observations for each gene in the new sample 
to be normalized 𝒂 ≔ The normalization parameter 
 
We replace the x term with the statistical distance and take the sum over all 
genes to find the overall penalty for a given value of 𝒂.   
 
𝑳 𝒙,𝒂 = 𝝁𝒊𝝈𝒊 𝟏𝟏 + 𝒆!(𝒙𝒊!𝒂𝝁𝒊)/𝝈𝒊 − 𝟏𝟐 𝟐  𝒊∈𝑰  
Equation 3 
 
The minimum value of 𝑳(𝒙,𝒂) solves this problem by determining the best 
value of 𝒂. This is true because the equation was written to assign lower values of 𝑳(𝒙,𝒂) to better solutions as defined by our model, i.e., where the reads of many 
genes in the new sample are similar to the reference range. That is, 𝒂∗ = 𝐚𝐫𝐠𝐦𝐢𝐧𝒂∈𝑨𝑳 𝒙,𝒂 . 
 
Logarithmic scale  
This method may also be performed on the logarithmic scale. This may 
particularly useful for RNA sequencing, where one may consider a decrease to 1/10 
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of the original expression level being of the same magnitude as an increase to 10 
times the original expression. This case is handled in a similar manner as the 
previous description involving a linear scale. All values in both the reference range 
and the sample are first log-transformed, and then used to calculate the mean and 
standard deviation.  
 
𝑳 𝒙,𝒂 = 𝝁𝒊𝝈𝒊 𝟏𝟏 + 𝒆!(𝒙𝒊!𝝁𝒊!𝐥𝐨𝐠  𝒂)/𝝈𝒊 − 𝟏𝟐 𝟐  𝒊∈𝑰  
Equation 4 
 
Note that the only difference in this equation is the substitution of (𝒙𝒊 − 𝝁𝒊 − 𝒂) 
for the distance term rather than the original (𝒙𝒊 − 𝒂𝝁𝒊). The value of 𝒂 is then added 
to all the log-transformed values from the original sample, and then they are 
transformed back to natural units. 
  
Other Loss Functions 
In addition to our proposed loss function, we explore three other loss 
functions: Huber’s T, Hampel’s 17A, and least squares. Each of these functions has a 
different set of properties, and represent different strategies to handle loss. Least 
squares is by far the most common loss function. It has a parabolic shape, and gives 
increasingly higher weight to outliers.  
 Huber’s T function acts like least squares when |𝒛| ≤ 𝒌, then increases linearly 
beyond this range (Figure 19). While this function does assign more loss to outliers, 
the loss increases linearly. We selected a value of 𝒌 = 𝟏 for our simulations and found 
that varying this parameter to values of 2 or 3 had little impact on results. Hampel’s 
17A function is similar to our function in respect to its tails, which become flat when 
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𝒛  becomes large (Figure 19). We used 𝒌 = 𝟏, 𝒃 = 𝟐 and 𝒄 = 𝟑 for Hampel’s 17A 
simulations. In all cases, we calculated 𝒛 as the statistical distance in the same 
manner as before, i.e., 𝒛 = (𝒙𝒊 − 𝒂𝝁𝒊)/𝝈𝒊 for a given value of 𝒂. 
 
   
Figure 19:	  Plot of Huber's T function with k=1 (left) and Hampel’s 17A function with 
parameters k=1, b=2, c=3 (right). 
 
Pre-normalization 
In practice, it was observed that the total number of reads obtained from a 
specimen varied widely. It was not uncommon to observe two similar samples that 
obtained a total number of reads that varied by more than ten fold. This may be due 
to many factors, but the major culprit is likely the quantity of amplifiable template 
present. Calculating the value of 𝒂 for a given sample will correct for this; however 
the possible values of 𝒂 would span a wide range of values in this case.  
We decide to pre-normalize samples so that the sum of all reads is the same for all 
samples. We calculate the normalized value, 𝒙𝒊!, as: 
 𝒙𝒊! = 𝒙𝒊𝒙𝒋𝒋∈𝑰        for all 𝒊 ∈ 𝑰 
Equation 5 
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This results in the sum of all 𝒙𝒊! being 1 regardless of the total number of reads 
obtained. This also insures that the values of 𝒂 fall over a much smaller range. 
Pseudocode 
 
1. Create a vector a.vec of enumerated values of 𝒂 
2. Obtain raw.counts vector from the new specimen 
3. Obtain ref.raw.counts matrix (genes x samples) from the reference range 
4. Pre-normalize raw.counts and each column of ref.raw.counts as: 
5.      norm.counts[i] = raw.counts[i]/sum(raw.counts) for i=1..gene.count 
6.      save result as norm.counts and ref.norm.counts 
7. Calculate the mean and s for each row of ref.norm.counts 
8. for each value i in a.vec 
9.      Loss.net=0 
10.    for (each gene j)  
11.             Loss.net += mean[j]/s[j]*(1/(1+exp(-(norm.counts [j]- 
                  a*mean[j])/sqrt(norm.counts [j])))-1/2)^2 
12.             Loss[i]=Loss.net 
13.     end for 
14. end for 
15. Determine which i results in the lowest 𝑳(𝒙,𝒂) (Equation 4), and select a[i] 
16. For visual inspection, create a plot with a.vec on the x-axis and Loss on the y- 
    axis 
17. Repeat above for each library if multiple libraries where used 
Table 3: Pseudocode used calculate 𝒂. 
 
Simulation 
We assume that there are a fixed number of reads, 𝒏, obtained from each 
sequencing run. In reality, various numbers of reads are obtained, but by pre-
normalizing the raw results we can achieve the same effective result. We define 𝒓𝒊 to 
be the average number of counts obtained for gene 𝒊 in the reference sample, and 𝒄𝒊 
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to be the number of counts obtained for gene 𝒊 in a patient sample. 𝑰 is the set of all 
genes in the panel. If we ignore stochastic effects and rounding, the number of reads 
detected, 𝒅𝒊, for each gene is: 
 𝒅𝒊 = 𝒏 𝒄𝒊𝒊∈𝑰 𝒄𝒊      for all 𝒊 ∈ 𝑰 
Equation 6 
Three major assumptions need to be made, regarding the mean, the standard 
deviation, and the number of genes in the panel. The mean and standard deviation 
describe the true distribution from which both the reference range and unaltered 
sample are drawn. For this purpose, we randomly generated reference range means 
from U(100,10000) and coefficient of variance was sampled from a uniform 
distribution with minimum and maximum values of 0.1 and 0.2 (i.e., U(0.1,0.2)). All 
variances/means were re-generated for each sample of this simulation. For each of 
the six samples in the reference range and the simulated patient sample, a value 
was generated by the distribution of that gene’s reference. If it is selected as an 
overexpressed gene, the simulated value was multiplied by the selected value to 
achieve the “overexpressed” read in the simulated patient sample.  
The calculation for the actual (correct) value of 𝒂, which we call 𝒂′, can be 
determined when data is simulated, allowing us to determine the accuracy of our 
algorithm when compared to the true value. By solving Equation 6 for 𝑐!, we realize 
that 𝑎′ is simply the inverse of the ratio: 
 𝑐! = !!!∈!! 𝑑! Therefore 
𝑎! = 𝑐!!∈!𝑛  
Equation 6 
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We have developed an R code to vary the two variables requested (proportion 
overexpressed and number of genes), and run multiple replicates such that we can 
obtain multiple estimates of 𝑎 for similar sets of conditions. Using these values, we 
can determine the standard deviation of the value of 𝑎 obtained. The pseudocode for 
this program is shown in Table 4.  
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1. Create a vector of overexpression levels (single value or sampled for 
distribution) 
2. Create a vector of gene counts to simulate (e.g., 10,20,30,…) 
3. Create a vector of proportion of genes overexpressed (e.g., 0, .1,..., 1) 
4. Define the number of reference samples (i.e., 6) and replicates (i.e., 100) 
5. for each value of i in the counts vector 
6.    for each value of j in the proportion vector 
7.         for each value of k in the replicates vector 
8.              sample mean from U(100,10000) for each gene (counts total genes) 
9.              sample sd from U(.1,.2)*mean for each gene 
10.             sample values for each of 6 reference range samples from N(mean, sd) 
11.              calculate mean (ref.mean) and standard deviation (ref.sd) from the   
                 reference range 
12.              sample a new result for each gene (new.sample) from N(mean, sd).      
                (This is our new sample that will be normalized) 
13.              select proportion*counts genes randomly from new.sample,  
                  then multiply each one by a value in levels, sampling a new value 
                  from levels for each one. (This simulates overexpression) 
14.              Calculate a.e, the expected value of the normalization parameter a,  
                 as sum(ref.means)/sum(new.sample) 
15.              Pre-normalize: new.sample=new.sample*sum(ref.means)/sum(new.sample) 
16.              determine a as the minimum value of the loss function 
17.         end for 
18.         calculate the mean value of (a.e-a)/a.e 
19.         calculate a.sd as the standard deviation of a over the replicates 
20.     end for 
21. end for 
Table 4: Pseudocode used to simulate values of a. 
 
In the first run of this simulation, all genes designated as altered experienced 
an overexpression of 5-fold. In Figure 20, we explore the difference between the 
value of 𝑎 we estimated and the true value of 𝑎. Note that our method is nearly 
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perfect until the proportion of genes overexpressed reaches 40%, then the accuracy 
drops substantially around 50%. We note no relationship between the number of 
genes and the variance of our estimate of 𝑎, indicating that our assay is suitable for 
both large and small panels of genes. 
 
  
Figure 20: Contour plot of the difference between the estimated value of 𝑎 and the 
actual value, 𝑎′, where all overexpressed genes experience a 5 fold increase. 
 
Figure 21 is interesting at it shows a massive loss in precision at the edge of 
the plateau. After some consideration, this loss of precision at the edge of the 
plateau makes sense. At this boundary, either group of points (the unaltered or 
overexpressed) may define the minimum, and very small stochastic effects 
determine which set (reference or overexpressed) achieves the lowest value. 
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Figure 21: Contour plot of standard deviation of the 𝑎 estimator as the proportion of 
5-fold overexpressed genes and the number of genes is varied. 
This is a fairly artificial situation as all genes are altered to the same extent. 
In practice, genes will be altered to varying levels. The strong dividing line we see 
here as the algorithm switches from treating the unaltered genes correctly to 
treating the overexpressed genes as unaltered would not occur in a real-life scenario, 
as genes are typically altered at varying levels. Additionally, stated assumption of 
this model was that genes would be altered to varying extents when they are 
overexpressed. 
The simulation was repeated under a more complex yet realistic scenario. As 
before, a proportion of genes was selected to be altered. Rather than setting all 
genes to be overexpressed 5 fold, we tried two other scenarios. First, we sampled 
the fold change from the normal distribution with mean 5 and standard deviation 3 
(Figure 22). Second, we tested a more skewed distribution by sampling the fold 
change from 𝑒!, where 𝑥 is distributed normal(0,3). The result from the second, 
skewed distribution is shown in Figure 23. 
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Figure 22: Contour plot of the difference between the estimated value of 𝑎 and 
the actual value, 𝑎′, where overexpressed genes experience a fold increase from 
N(5,3). 
 
  
 
Figure 23: Contour plot of the difference between the estimated value of 𝑎 and 
the actual value, 𝑎′, where overexpressed genes experience a fold increase from 𝑒! , 𝑥~𝑁(0,3). 
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Figure 24: Contour plot of the difference between the estimated value of 𝑎 and the 
actual value, 𝑎′, where genes are underexpressed to 0.01 fold the original level. 
 
In order to better understand the distribution of results obtained, we used the 
simulation to generate histograms of the values of 𝑎 obtained, expressed as (actual-
expected)/expected. Figure 25 shows these histograms, with various values of 
proportion overexpressed and gene counts explored.  Note that only three different 
values of gene counts were explored, as this factor doesn’t appear to affect the 
results. 100 replicates were used for each histogram, and genes were overexpressed 
exactly 5 fold. These results further demonstrate that the method is fairly stable 
even under a worst-case scenario such as this one.  
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Figure 25: Histograms of (actual-expected)/expected values of 𝑎 for various 
combinations of genes and proportion overexpressed, where genes are 
overexpressed 5 fold. The linear method was used for this figure. 
 
The effects of various loss functions were explored. The results of the 
scenario where overexpression is distributed as normal (5,3) was selected for this 
simulation because we decided this scenario was the most representative of the 
types of data we would experience in routine clinical testing. The results are shown 
in Figure 26. An interesting trend is immediately observable: the behavior at the 
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extremes of a loss function determines how well the function can normalize. As 
expected, functions that give increasing weight to outliers, such as least squares, 
perform poorly. Functions that become flat at the extremes, which effectively give 
less weight to outliers, perform the best. Our method and Hampel’s 17A function fall 
into this category, and they show similar and effective normalization. Huber’s T 
function has linear behavior at the extremes, and as expected performs at a level 
better than least squares but inferior to functions with flatter tails.  
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Figure 26: Contour plot of the difference between the estimated value of 𝑎 and the 
actual value, 𝑎′, where overexpressed genes experience a fold increase distributed 
N(5,3) using different loss functions: our proposed method (top left), Huber’s T (top 
right), Hampel’s 17A (bottom left), and least squares (bottom right). The color scale 
ranges from -7 to +7. 
 
 
Application 
Six colon and six lung cases were processed. Each case included both tumor and 
adjacent normal specimen, and both specimens were provided in both frozen and 
formalin-fixed, paraffin-embedded (FFPE) format. Thus, each case provided four 
specimens. We selected both FFPE and frozen specimens because they are 
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completely different formats of the same specimen. If we can analyze both and get 
similar results, we can demonstrate that our method is consistent. While the raw 
results initially look completely different between FFPE and frozen specimens, 
especially in respect to mean and variance of gene expression, we should detect 
similar results after normalizing as both specimens are experiencing the same 
underlying molecular events. Upon analysis of the results, it was clear that the set of 
four specimens provided for three of the lung cases did not match each other based 
on germline SNPs, and thus, these were eliminated from the analysis yielding a final 
set of six colon and three lung cases. 
Analytes were extracted, then quantified and normalized. The Highpure FFPE 
RNA micro kit (Roche 04823125001) was used. The protocol was modified slightly to 
use a heptane/methanol precipitation to deparaffinize. The DNA was purified with the 
QiaAmp DNA FFPE tissue kit (Qiagen 56404). The quantity of RNA and DNA was 
quantified with the Qubit fluorometer, then adjusted to a fixed concentration. The 
volumes were reduced to a minimum of 100uL for DNA and 20uL for RNA in attempts 
to reach the target concentration. 
Libraries were created via PCR. RNA was converted to cDNA via a proprietary 
process. Libraries were then built via PCR, with four replicates being created for each 
library. The ExoSAP-IT reagent was used to remove unincorporated primers, then 
libraries from a single patient were mixed. 
Sequencing occurred via the standard Ion Torrent sequencing protocol 
provided by Life Technologies using 318 chips. On some of the colon samples, the 
RNA needed to be repeated. In this case, the RNA only was run on 314 chips, which 
resulted in similar coverage to that obtained by combined RNA and DNA on a 318 
chip. 
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Sample Plots of a, the Normalization Parameter 
Figure 27 shows loss plots (plots of 𝑎 vs. 𝐿(𝑥, 𝑎)) obtained from a 
tumor/normal pair from a lung adenocarcinoma patient. Note the smooth, inverted 
bell curve shape of the normal specimen, as expected. The x-axis is the value of 1/𝑎, 
and the y-axis is the loss. We expect smooth bell shaped curves for the normal as is 
seen in Figure 27. When overexpressed genes are present in a tumor specimen 
(right), we observed skewedness towards higher levels of 1/𝑎 and multiple local 
minima. We choose to plot 1/𝑎 on the x-axis rather than 𝑎 to make the chart more 
intuitive to view. The tumor specimen shows overexpression of genes in the library 
depicted by red, causing a skewed distribution shape and decrease in optimal 1/𝑎 to 
compensate. As discussed in Chapter 3, the RNA expression assays were split into 
four multiplexes. Because each multiplex is normalized separately, this process was 
run four times, yielding four independent optimal values of 1/𝑎. 
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Figure 27: Expression normalization loss plots for various values of 𝑎 in a healthy 
tissue (left) and a cancer tissue (right). The x-axis the value of 1/𝑎, and the y value 
is loss. Each color indicates a different library (set of multiplexed assays), and the 
dot on each line shows the optimal value found for 1/𝑎. 
 
Discussion 
We created a method to normalize new results against a reference range that is 
robust to outliers. Unlike other methods, our method does not require identification 
of outliers. This is a key distinction, because it eliminates the need to make an 
assumption that may not hold true for all instances and removes any subjectivity 
from the interpretation of results. We use a robust loss function in a manner similar 
to robust regression.  
This strategy is novel and is robust to extreme outlines within the dataset. 
Data was simulated by adding random noise to known values, and the accuracy was 
measured by comparison of the normalized values to the known values that were 
used to simulate the data. This strategy is in many ways ideal because at the time of 
 78 
writing, there is no accepted method to establish baseline truth in complex molecular 
expression results, making it impossible to have a comparator to determine the 
accuracy of our results. 
We explored a variety of loss functions for this robust normalization method. 
In general, those that gave less weight to outliers performed better. Examples of 
functions that perform well are our proposed function and Hampel’s 17A. Functions 
that give increasing weight to outliers, i.e., least squares, performed poorly. Huber’s 
T function gives increasing weight to outliers on a linear basis and showed 
intermediate performance as expected. 
 We are currently running a series of patient samples in duplicate to better 
understand precision of the normalized result obtained with this method. We have 
shown that the same specimen can be processed in FFPE and frozen formats with 
similar results obtained. We are also running other methods to assess gene 
expression and copy number (such as FISH and IHC) to compare our method to the 
current standard. While FISH and IHC are only available for a small subset of the 
genes in our panel, this strategy provides additional evidence that our method works 
for at least some subset of the assays within the panel. 
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CHAPTER 5 
CONCLUSIONS AND FUTURE WORK 
We have successfully applied a variety of mathematical techniques to various 
aspects of NGS. While there are many components required to analyzed NGS data, 
we selected ones that posed major hurtles in regard to computational complexity, 
assay design and steps critical to accuracy that currently do not have viable 
solutions. Certain steps that are well defined with clear solutions were not altered, as 
suitable solutions already exist. In the second chapter, we described simple 
algorithm to analyze SNP results to determine whether two samples are from the 
same patient. In the third chapter, we describe a method to multiplex the assays 
that are used in NGS. In the fourth chapter, we describe a method to normalize 
results obtained from NGS, allowing direct comparison between a patient specimen 
and a reference range of disease-free specimens. All of these methods have a similar 
theme: they directly address a specific issue demanded by clinical medicine, and 
they all have very low computational complexity. These aspects are interrelated, as a 
clinical test offered to large numbers of patients must use a reasonable amount of 
computing power. If too much computing power were required, the test would not be 
feasible. Computational analysis is currently not reimbursable by insurance or 
Medicare and thus it would be impossible to fund capital or operational expenses of a 
large computing infrastructure. 
At the time of writing, all of these projects are in use for their designed 
purpose. The specimen comparison algorithms discussed the second chapter are 
used routinely in TCGA project. They replaced algorithms that required nearly a full 
days’ worth of computational power on a major hospital’s network, and produced 
better sensitivity and specificity. The multiplexing method discussed in the third 
chapter is routinely used to design new multiplexes when assays are added to PCR-
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based tests offered by Paradigm Diagnostics and Viomics Inc. The normalization 
method is used by Paradigm Diagnostics for analyzing every patient case, and is also 
used by International Genomics Consortium for various research projects. 
 This work can be extended in many aspects. More in-depth research into the 
current work may be conducted, or similar solutions may be created for other 
problems. For example, the multiplexing algorithm can be expanded to estimate the 
cost of the number of multiplexes into the objective function. While there is not a 
one-size-fits-all solution for this, ad hoc solutions can be made for specific projects. 
For example, in the Paradigm Diagnostics’ test, the tubes used come in strips of four, 
so there is little cost to increase from three to four multiplexes, but substantial 
additional cost to move from 4 to 5. The normalization algorithm can be modified to 
account for Poisson variance, i.e., variance that is related to the number of counts 
obtained. This was attempted in the current study, but was not needed because 
most genes had coverage (i.e., number of counts) greater than 500, so Poisson 
variance contributed a trivial amount of variance when compared to the average 
coefficient of variance of 40% observed. However, if genes frequently had lower 
coverage (increasing Poisson variance) or an application with less variance due to 
intrinsic biological factors was used (decreasing variance from other sources), it may 
become valuable to incorporate a calculation for Poisson variance into the variance 
calculation. 
 This research may also be expanded into similar project types. For example, 
understanding the subclonal makeup of tumors of major interest at the time of 
writing. Tumors often consist of multiple subclones, or distinctly different populations 
of cells rather than a single, uniform collection of cells. These subclones are usually 
progressive, i.e., they occur in sequence, which each new subclone obtaining new 
events. Some events, such as copy number and mutation, occur in integral 
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quantities and thus may be well understood by a well-designed integer program. 
Other events, such as gene expression, are continuous and can be well understood 
by datamining-type techniques or mixed integer programs. There are likely 
applications for methods based on loss functions, similar to the strategy used in 
chapter 4. For example, such a loss function could be used as an objective function, 
although this would yield a non-convex problem that could only be practically solved 
with a small number of variables. 
 We have successfully created low-complexity models for complex biological 
phenomena directly related to clinical medicine by carefully tailoring models to 
specific purposes. While these methods are not as broadly applicable as the 
datamining methods used in medical research, they are highly suitable for clinical 
medicine. While the bioinformatics field as a whole is rapidly evolving to more 
complex and generalized methods, our strategy of efficient and specific methods is 
key to bringing discoveries from the intellectual to practical. 
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